67603-23-0

Upstream product

• 13312-81-7 2-hydroxy-2-[2-nitrophenyl]acetonitrile 
• 7647-01-0 hydrogenchloride 
• 100948-24-1 α-[(trimethylsilyl)oxy]-α-(o-nitrophenyl)acetonitrile 
• 552-89-6 2-nitro-benzaldehyde 
• 35928-59-7 2,2-dibromo-1-(2-nitrophenyl)ethan-1-one 

Downstream Products

• 97522-67-3 C₁₃H₈N₂O₃S 
• 144366-41-6 Hydroxy-(2-nitroso-phenyl)-acetic acid 
• 552-16-9 ortho-nitrobenzoic acid 
• 14602-44-9 2-nitro-L-mandelic acid-ethyl ester 
• 64357-06-8 1-hydroxy-indoline-2,3-dione-3-phenylhydrazone 
• 144366-50-7 N-(phenylsulfonyl) N-<2-(α-hydroxycarboxymethyl)phenyl>hydroxylamine 
• 97522-69-5 C₁₃H₁₀N₂OS 
• 191476-05-8 t-butyl 2-acetoxy-2-[2-nitrophenyl] acetate 
• 191476-01-4 t-butyl 2-hydroxy-2-[2-nitrophenyl]acetate 
• 103262-47-1 2-acetoxy-2-[2-nitrophenyl]acetic acid 
• 610-33-3 (2-nitro-phenyl)-glyoxylic acid 
• 14602-44-9 2-nitro-mandelic acid-ethyl ester 
• 1345834-28-7 Nmoc₂-pentamidine 

Relevant academic research and scientific papers

Synthesis and characterisation of α-carboxynitrobenzyl photocaged L-aspartates for applications in time-resolved structural biology

We report a new synthetic route to a series of α-carboxynitrobenzyl photocaged l-aspartates for application in time-resolved structural biology. The resulting compounds were characterised in terms of UV/Vis absorption properties, aqueous solubility and stability, and photocleavage rates (τ = μs to ms) and quantum yields (φ = 0.05 to 0.14).

INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X, Y, Z, D, R1, R2, R3, R4, R12, R15nd R16 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use as modulators of mGluR7.

COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION

Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.

Light-controlled DNA binding of bisbenzamidines

Caging of the amidinium moieties of two representative bisbenzamidine DNA binders with suitable photoresponsive protecting groups suppresses their DNA-binding, which can then be fully recovered upon irradiation with UV light that removes the caging groups

Non-photochemical rearrangements of o-nitrobenzyl compounds

Three rearrangements of 2-nitrobenzyl compounds with increasingly complex structural changes are described. The first is a remarkably facile conversion of 2-nitrobenzyl triflate to 2-nitrosobenzaldehyde. The second is an unexpected formation of 1-acetyl-2

7-α-Amino-substituted acylamino-3-(1-carboxymethyltetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acids

Certain 7-acylamido-3-(1-carboxy-loweralkyl-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acids and their salts and easily hydrolyzed esters of the 4-carboxyl group were synthesized and found to be potent antibacterial agents which exhibited good aqueous solubility. In a preferred embodiment the 7-substituent was 2'-aminomethylphenylacetamido.

7-(D-α-Hydroxy-2-arylacetamido)-3-(2-carboxyalkyl-2,3-dihydro-s-triazolo-[4,3-b]pyridazin-3-on-6-ylthiomethyl)-3-cephem-4-carboxylic acids and derivatives

7-(D-α-Hydroxy-2-arylacetamido)-3-(2-carboxyalkyl-2,3-dihydro-s-triazolo[4,3-b]pyridazin-3-on-6-ylthiomethyl)-3-cephem-4-carboxylic acids and derivatives containing blocking groups on the α-hydroxy group and their nontoxic, pharmaceutically acceptable salts are valuable as antibacterial agents and are particularly valuable as therapeutic agents in poultry and in animals, including man, in the treatment of infectious diseases caused by many Gram-positive and Gram-negative bacteria. A preferred compound is 7-(D-mandelamido)-3-(2-carboxyalkyl-2,3-dihydro-s-triazolo[4,3-b]pyridazin-3-on-6-ylthiomethyl)-3-cephem-4-carboxylic acid.

7-(D-α-Hydroxy-2-arylacetamido)-3-(tetrazolo-[4,5-b]pyridazin-6-ylthiomethyl)-3-cephem-4-carboxylic acids

7-(D-α-Hydroxy-2-arylacetamido)-3-(tetrazolo-[4,5-b]pyridazin-6-ylthiomethyl)-3-cephem-4-carboxylic acids and their nontoxic, pharmaceutically acceptable salts are valuable as antibacterial agents and are particularly valuable as therapeutic agents in poultry and animals, including man, in the treatment of infectious diseases caused by many Gram-positive and Gram-negative bacteria.